United Therapeutics provides support for patients on Orenitram
The Orenitram 90-Day Trial Program allows you to assess how well your patients tolerate Orenitram
- The program is offered to eligible patients at no cost for up to 90 days
- Your patients have no obligation to continue taking Orenitram at the end of the trial period
- Eligibility for this program is limited to patients with PAH (WHO Group 1) who have never been treated with Orenitram. Patients transitioning from another treprostinil medication are not eligible for this program
Copay Assistance Program
Eligibility Requirements For This Program
Patients must be 18 years or older to use this program.
Patients using Medicare, Medicaid, or any other state or federal government program to pay for their medications are not eligible. Patients who start utilizing government coverage during the term of the program will no longer be eligible.
The program is valid only for patients with commercial (also known as private) insurance who are taking the medication for an FDA-approved indication. The program is only valid for the cost of Orenitram and not applicable to any related supplies or other medical expenses associated with administering the product.
Eligible patients must be residents of the United States or Puerto Rico.
The program is subject to additional state law restrictions. Patients residing in select states may not be eligible for the program.
Access and financial assistance
Helping patients determine if they qualify for United Therapeutics’ Patient Assistance Programs
ASSIST, the Access Solutions and Support Team, is a United Therapeutics resource committed to helping eligible patients obtain access to their prescribed therapies. ASSIST can help PAH patients navigate topics such as insurance coverage, available financial assistance, and in-network pharmacies.
ASSIST offers support during the referral process
Through ASSIST, the Orenitram Referral Portal allows you to track the status of prescriptions for your patients who have been prescribed Orenitram.
Once you prescribe and submit the initial referral form, ASSIST will:Directly download referral form view example referral form
To contact ASSIST, CALL 1-877-UNITHER (1-877-864-8437) or go to: www.UTAssist.com
iAssist: Simple online referral system
Orenitram is simplifying the referral process with iAssist
iAssist is a centralized hub for Orenitram that helps initiate and facilitate the referral process for you and your patients. At no cost to you, treatment with Orenitram now comes with a streamlined solution that includes:ACCESS iASSIST
Important Safety Information
- Avoid use of Orenitram in patients with severe hepatic impairment (Child Pugh Class C) due to increases in systemic exposure.
Warnings and Precautions
- Abrupt discontinuation or sudden large reductions in dosage of Orenitram may result in worsening of PAH symptoms.
- The Orenitram tablet shell does not dissolve. In patients with diverticulosis, Orenitram tablets can lodge in a diverticulum.
- In the 12-week, placebo-controlled, monotherapy study, and an event-driven, placebo-controlled, combination therapy study, adverse reactions that occurred at rates at least 5% higher on Orenitram than on placebo included headache, diarrhea, nausea, vomiting, flushing, pain in jaw, pain in extremity, hypokalemia, abdominal discomfort, and upper abdominal pain.
- Co-administration of Orenitram and the CYP2C8 enzyme inhibitor gemfibrozil increases exposure to treprostinil; therefore, Orenitram dosage reduction may be necessary in these patients.
- Animal reproductive studies with Orenitram have shown an adverse effect on the fetus. There are no adequate and well-controlled studies with Orenitram in pregnant women.
- It is not known whether treprostinil is excreted in human milk or if it affects the breastfed infant or milk production.
- Safety and effectiveness of Orenitram in pediatric patients have not been established.
- Use of Orenitram in patients aged 65 years and over demonstrated slightly higher absolute and relative adverse event rates compared to younger patients. Caution should be used when selecting a dose for geriatric patients.
- There is a marked increase in the systemic exposure to treprostinil in hepatically impaired patients.
Orenitram is a prostacyclin mimetic indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity. The studies that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (66%) or PAH associated with connective tissue disease (26%).
PAH=pulmonary arterial hypertension; WHO=World Health Organization.